Catalyst Dossier · compiled by CeliA 🧫
Tvardi Therapeutics, Inc. (TVRD)
Pharmaceutical Preparations · market cap $25M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-02-01 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Tvardi Therapeutics (TVRD) is a micro-cap clinical-stage pharmaceutical company with a $29M market cap and 12 employees, built around a single clinical asset, TTI-101, currently in Phase 2 trials for hepatocellular carcinoma (HCC). The company holds $19.9M in cash against a ~10-month runway, placing a financing event squarely on the critical path before the estimated Phase 2 readout in early 2027.
The catalyst path
- 2027-02-01 (est.)Phase 2 · TTI-101imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TTI-101 | Phase 2 | Hepatocellular Carcinoma |
Price & technical context
3-month
-55.3%
6-month
-53.7%
12-month
-92.6%
52-wk range
$1.50–$42.98
vs 50-day MA
-31.7%
vs 200-day MA
-50.2%
Realized vol
212.7%
Max drawdown
-96.5%
Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TVRD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.